Review: Unchained maladie - a reassessment of the role of Ubb +1-capped polyubiquitin chains in Alzheimer's disease

Neuropathology and Applied Neurobiology

Volumn 38, Issue 2, 2012, Pages 118-131

  Chadwick, L ^a   Gentle, L ^a   Strachan, J ^a   Layfield, R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Frameshift ubiquitin mutant; MARK; Proteasome; Ubb +1; Ubiquitin; Unanchored polyubiquitin

Indexed keywords

AMYLOID BETA PROTEIN; DNA 26S; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOTRANSFERASE; POLYUBIQUITIN; PROTEASOME; TAU PROTEIN; UBIQUITIN CAPPED POLYUBIQUITIN CHAIN; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; CARBOXY TERMINAL SEQUENCE; CATALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HUMAN; MOLECULAR DYNAMICS; MOLECULAR MISREADING; MUTATION; NEUROPATHOLOGY; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; FRAMESHIFT MUTATION; GENE EXPRESSION REGULATION; HUMANS; MICE; NF-KAPPA B; POLYUBIQUITIN; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; TAU PROTEINS; UBIQUITIN;

EID: 84857892217     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2011.01236.x     Document Type: Review

References (119)

1. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003; 40: 427-46
2. Kirisako T, Kamei K, Murata S, Kato M, Fukumoto H, Kanie M, Sano S, Tokunaga F, Tanaka K, Iwai K. A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J 2006; 25: 4877-87
3. Kim HT, Kim KP, Lledias F, Kisselev AF, Scaglione KM, Skowyra D, Gygi SP, Goldberg AL. Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages. J Biol Chem 2007; 282: 17375-86
4. Jacobson AD, Zhang NY, Xu P, Han KJ, Noone S, Peng J, Liu CW. The lysine 48 and lysine 63 ubiquitin conjugates are processed differently by the 26 S proteasome. J Biol Chem 2009; 284: 35485-94
5. Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular signals -'Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008; 9: 536-42
6. Xu P, Duong DM, Seyfried NT, Cheng D, Xie Y, Robert J, Rush J, Hochstrasser M, Finley D, Peng J. Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 2009; 137: 133-45
7. Komander D, Reyes-Turcu F, Licchesi JD, Odenwaelder P, Wilkinson KD, Barford D. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep 2009; 10: 466-73
8. Adhikari A, Chen ZJ. Diversity of polyubiquitin chains. Dev Cell 2009; 16: 485-6
9. Dikic I, Wakatsuki S, Walters KJ. Ubiquitin-binding domains - from structures to functions. Nat Rev Mol Cell Biol 2009; 10: 659-71
10. Miller J, Gordon C. The regulation of proteasome degradation by multi-ubiquitin chain binding proteins. FEBS Lett 2005; 579: 3224-30
11. Su V, Lau AF. Ubiquitin-like and ubiquitin-associated domain proteins: significance in proteasomal degradation. Cell Mol Life Sci 2009; 66: 2819-33
12. Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes. BBA-Mol. Cell Res 2004; 1695: 189-207
13. Reyes-Turcu FE, Wilkinson KD. Polyubiquitin binding and disassembly by deubiquitinating enzymes. Chem Rev 2009; 109: 1495-508
14. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005; 123: 773-86
15. Reyes-Turcu FE, Shanks JR, Komander D, Wilkinson KD. Recognition of polyubiquitin isoforms by the multiple ubiquitin binding modules of isopeptidase T. J Biol Chem 2008; 283: 19581-92
16. Piotrowski J, Beal R, Hoffman L, Wilkinson KD, Cohen RE, Pickart CM. Inhibition of the 26 S proteasome by polyubiquitin chains synthesized to have defined lengths. J Biol Chem 1997; 272: 23712-21
17. Dayal S, Sparks A, Jacob J, Allende-Vega N, Lane DP, Saville MK. Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J Biol Chem 2009; 284: 5030-41
18. Reyes-Turcu FE, Horton JR, Mullally JE, Heroux A, Cheng X, Wilkinson KD. The ubiquitin binding domain ZnF UBP recognizes the C-terminal diglycine motif of unanchored ubiquitin. Cell 2006; 124: 1197-208
19. Zhao YL, Hegde AN, Martin KC. The ubiquitin proteasome system functions as an inhibitory constraint on synaptic strengthening. Curr Biol 2003; 13: 887-98
20. Patrick GN. Synapse formation and plasticity: recent insights from the perspective of the ubiquitin proteasome system. Curr Opin Neurobiol 2006; 16: 90-4
21. Upadhya SC, Ding L, Smith TK, Hegde AN. Differential regulation of proteasome activity in the nucleus and the synaptic terminals. Neurochem Int 2006; 48: 296-305
22. Jakawich SK, Neely RM, Djakovic SN, Patrick GN, Sutton MA. An essential postsynaptic role for the ubiquitin proteasome system in slow homeostatic synaptic plasticity in cultured hippocampal neurons. Neuroscience 2010; 171: 1016-31
23. Mabb AM, Ehlers MD. Ubiquitination in postsynaptic function and plasticity. Annu Rev Cell Dev Biol 2010; 26: 179-210
24. de Vrij FM, Fischer DF, van Leeuwen FW, Hol EM. Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Prog Neurobiol 2004; 74: 249-70
25. Oddo S. The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med 2008; 12: 363-73
26. Dennissen FJ, Kholod N, Steinbusch HW, Van Leeuwen FW. Misframed proteins and neurodegeneration: a novel view on Alzheimer's and Parkinson's diseases. Neurodegener Dis 2010; 7: 76-9
27. Riederer BM, Leuba G, Vernay A, Riederer I. The role of the ubiquitin proteasome system in Alzheimer's disease. Exp Biol Med (Maywood) 2011; 236: 268-76
28. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem 2000; 75: 436-9
29. van Leeuwen FW, Burbach JP, Hol EM. Mutations in RNA: a first example of molecular misreading in Alzheimer's disease. Trends Neurosci 1998; 21: 331-5
30. van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, Koycu S, Ramdjielal RD, Salehi A, Martens GJ, Grosveld FG, Peter J, Burbach H, Hol EM. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 1998; 279: 242-7
31. Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, Mayer RJ, Layfield R. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Natl Acad Sci U S A 2000; 97: 9902-6
32. Dennissen FJ, Kholod N, Hermes DJ, Kemmerling N, Steinbusch HW, Dantuma NP, van Leeuwen FW. Mutant ubiquitin (UBB(+1)) associated with neurodegenerative disorders is hydrolyzed by ubiquitin C-terminal hydrolase L3 (UCH-L3). FEBS Lett 2011; 585: 2568-74
33. Layfield R. Does an inhibition of the uhiquitin/26S proteasome pathway of protein degradation underlie the pathogenesis of non-familial Alzheimer's disease? Med Hypotheses 2001; 56: 395-9
34. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Titani K, Ihara Y. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 1993; 10: 1151-60
35. Bancher C, Grundkeiqbal I, Iqbal K, Fried VA, Smith HT, Wisniewski HM. Abnormal phosphorylation of tau precedes ubiquitination in neurofibrillary pathology of Alzheimer disease. Brain Res 1991; 539: 11-18
36. Fraser PE, Levesque G, Yu G, Mills LR, Thirlwell J, Frantseva M, Gandy SE, Seeger M, Carlen PL, George-Hyslop P. Presenilin 1 is actively degraded by the 26S proteasome. Neurobiol Aging 1998; 19: S19-21
37. Marambaud P, Ancolio K, Lopez-Perez E, Checler F. Proteasome inhibitors prevent the degradation of familial Alzheimer's disease-linked presenilin 1 and potentiate A beta 42 recovery from human cells. Mol Med 1998; 4: 147-57
38. Steiner H, Capell A, Pesold B, Citron M, Kloetzel PM, Selkoe DJ, Romig H, Mendla K, Haass C. Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation. J Biol Chem 1998; 273: 32322-31
39. de Pril R, Fischer DF, Maat-Schieman ML, Hobo B, de Vos RA, Brunt ER, Hol EM, Roos RA, van Leeuwen FW. Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum Mol Genet 2004; 13: 1803-13
40. van Leeuwen FW, Kros JM, Kamphorst W, van Schravendijk C, de Vos RA. Molecular misreading: the occurrence of frameshift proteins in different diseases. Biochem Soc Trans 2006; 34: 738-42
41. Fergusson J, Landon M, Lowe J, Ward L, van Leeuwen FW, Mayer RJ. Neurofibrillary tangles in progressive supranuclear palsy brains exhibit immunoreactivity to frameshift mutant ubiquitin-B protein. Neurosci Lett 2000; 279: 69-72
42. Lindsten K, de Vrij FM, Verhoef LG, Fischer DF, van Leeuwen FW, Hol EM, Masucci MG, Dantuma NP. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J Cell Biol 2002; 157: 417-27
43. Hope AD, de Silva R, Fischer DF, Hol EM, van Leeuwen FW, Lees AJ. Alzheimer's associated variant ubiquitin causes inhibition of the 26S proteasome and chaperone expression. J Neurochem 2003; 86: 394-404
44. Fischer DF, van Dijk R, van Tijn P, Hobo B, Verhage MC, van der Schors RC, Li KW, van Minnen J, Hol EM, van Leeuwen FW. Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin. Neurobiol Aging 2009; 30: 847-63
45. van Tijn P, Hobo B, Verhage MC, Oitzl MS, van Leeuwen FW, Fischer DF. Alzheimer-associated mutant ubiquitin impairs spatial reference memory. Physiol Behav 2010; 102: 193-200
46. van Tijn P, Verhage MC, Hobo B, van Leeuwen FW, Fischer DF. Low levels of mutant ubiquitin are degraded by the proteasome in vivo. J Neurosci Res 2010; 88: 2325-37
47. Brion JP, Power D, Hue D, Couck AM, Anderton BH, Flament-Durand J. Heterogeneity of ubiquitin immunoreactivity in neurofibrillary tangles of Alzheimer's disease. Neurochem Int 1989; 14: 121-8
48. Crystal AS, Morais VA, Fortna RR, Carlin D, Pierson TC, Wilson CA, Lee VM, Doms RW. Presenilin modulates Pen-2 levels posttranslationally by protecting it from proteasomal degradation. Biochemistry 2004; 43: 3555-63
49. He G, Qing H, Cai F, Kwok C, Xu H, Yu G, Bernstein A, Song W. Ubiquitin-proteasome pathway mediates degradation of APH-1. J Neurochem 2006; 99: 1403-12
50. He G, Qing H, Tong Y, Cai F, Ishiura S, Song W. Degradation of nicastrin involves both proteasome and lysosome. J Neurochem 2007; 101: 982-92
51. Bergman A, Hansson EM, Pursglove SE, Farmery MR, Lannfelt L, Lendahl U, Lundkvist J, Naslund J. Pen-2 is sequestered in the endoplasmic reticulum and subjected to ubiquitylation and proteasome-mediated degradation in the absence of presenilin. J Biol Chem 2004; 279: 16744-53
52. Flood F, Murphy S, Cowburn RF, Lannfelt L, Walker B, Johnston JA. Proteasome-mediated effects on amyloid precursor protein processing at the gamma-secretase site. Biochem J 2005; 385: 545-50
53. Cripps D, Thomas SN, Jeng Y, Yang F, Davies P, Yang AJ. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem 2006; 281: 10825-38
54. Goldberg AL, Cascio P, Saric T, Rock KL. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 2002; 39: 147-64
55. Pickart CM. Ubiquitin in chains. Trends Biochem Sci 2000; 25: 544-8
56. Brown MR, Bondada V, Keller JN, Thorpe J, Geddes JW. Proteasome or calpain inhibition does not alter cellular tau levels in neuroblastoma cells or primary neurons. J Alzheimers Dis 2005; 7: 15-24
57. Delobel P, Leroy O, Hamdane M, Sambo AV, Delacourte A, Buee L. Proteasome inhibition and Tau proteolysis: an unexpected regulation. FEBS Lett 2005; 579: 1-5
58. Liu YH, Wei W, Yin J, Liu GP, Wang Q, Cao FY, Wang JZ. Proteasome inhibition increases tau accumulation independent of phosphorylation. Neurobiol Aging 2009; 30: 1949-61
59. Tollervey JR, Wang Z, Hortobagyi T, Witten JT, Zarnack K, Kayikci M, Clark TA, Schweitzer AC, Rot G, Curk T, Zupan B, Rogelj B, Shaw CE, Ule J. Analysis of alternative splicing associated with aging and neurodegeneration in the human brain. Genome Res 2011; 21: 1572-82
60. Fischer DF, De Vos RA, Van Dijk R, De Vrij FM, Proper EA, Sonnemans MA, Verhage MC, Sluijs JA, Hobo B, Zouambia M, Steur EN, Kamphorst W, Hol EM, Van Leeuwen FW. Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. FASEB J 2003; 17: 2014-24
61. Gerez L, de Haan A, Hol EM, Fischer DF, van Leeuwen FW, van Steeg H, Benne R. Molecular misreading: the frequency of dinucleotide deletions in neuronal mRNAs for beta-amyloid precursor protein and ubiquitin B. Neurobiol Aging 2005; 26: 145-55
62. Hol EM, van Leeuwen FW, Fischer DF. The proteasome and Alzheimer's disease and Parkinson's disease : lessons from ubiquitin B+1. Trends Mol Med 2005; 11: 488-95
63. van Tijn P, de Vrij FM, Schuurman KG, Dantuma NP, Fischer DF, van Leeuwen FW, Hol EM. Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease. J Cell Sci 2007; 120: 1615-23
64. Cook C, Gass J, Dunmore J, Tong J, Taylor J, Eriksen J, McGowan E, Lewis J, Johnston J, Petrucelli L. Aging is not associated with proteasome impairment in UPS reporter mice. PLoS ONE 2009; 4: Article No.: e 5888.
65. Oddo S, Caccamo A, Tseng B, Cheng D, Vasilevko V, Cribbs DH, LaFerla FM. Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci 2008; 28: 12163-75
66. Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 2003; 85: 115-22
67. Upadhya SC, Hegde AN. Role of the ubiquitin proteasome system in Alzheimer's disease. BMC Biochem 2007; 8: S12
68. Hegde AN, Upadhya SC. The ubiquitin-proteasome pathway in health and disease of the nervous system. Trends Neurosci 2007; 30: 587-95
69. Cajigas IJ, Will T, Schuman EM. Protein homeostasis and synaptic plasticity. EMBO J 2010; 29: 2746-52
70. Tan Z, Sun X, Hou FS, Oh HW, Hilgenberg LG, Hol EM, van Leeuwen FW, Smith MA, O'Dowd DK, Schreiber SS. Mutant ubiquitin found in Alzheimer's disease causes neuritic beading of mitochondria in association with neuronal degeneration. Cell Death Differ 2007; 14: 1721-32
71. Tank EM, True HL. Disease-associated mutant ubiquitin causes proteasomal impairment and enhances the toxicity of protein aggregates. PLoS Genet 2009; 5: Article No.: e1000382.
72. Ko S, Kang GB, Song SM, Lee JG, Shin DY, Yun JH, Sheng Y, Cheong C, Jeon YH, Jung YK, Arrowsmith CH, Avvakumov GV, Dhe-Paganon S, Yoo YJ, Eom SH, Lee W. Structural basis of E2-25K/UBB+1 interaction leading to proteasome inhibition and neurotoxicity. J Biol Chem 2010; 285: 36070-80
73. Song S, Kim SY, Hong YM, Jo DG, Lee JY, Shim SM, Chung CW, Seo SJ, Yoo YJ, Koh JY, Lee MC, Yates AJ, Ichijo H, Jung YK. Essential role of E2-25K/Hip-2 in mediating amyloid-beta neurotoxicity. Mol Cell 2003; 12: 553-63
74. Song S, Lee H, Kam TI, Tai ML, Lee JY, Noh JY, Shim SM, Seo SJ, Kong YY, Nakagawa T, Chung CW, Choi DY, Oubrahim H, Jung YK. E2-25K/Hip-2 regulates caspase-12 in ER stress-mediated A beta neurotoxicity. J Cell Biol 2008; 182: 675-84
75. Xia ZP, Sun L, Chen X, Pineda G, Jiang X, Adhikari A, Zeng W, Chen ZJ. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 2009; 461: 114-19
76. Mattson MP, Meffert MK. Roles for NF-kappa B in nerve cell survival, plasticity, and disease. Cell Death Differ 2006; 13: 852-60
77. Ivins FJ, Montgomery MG, Smith SJ, Morris-Davies AC, Taylor IA, Rittinger K. NEMO oligomerization and its ubiquitin-binding properties. Biochem J 2009; 421: 243-51
78. Gautheron J, Courtois G. 'Without Ub I am nothing': NEMO as a multifunctional player in ubiquitin-mediated control of NF-kappa B activation. Cell Mol Life Sci 2010; 67: 3101-13
79. Kulathu Y, Akutsu M, Bremm A, Hofmann K, Komander D. Two-sided ubiquitin binding explains specificity of the TAB2 NZF domain. Nat Struct Mol Biol 2009; 16: 1328-30
80. Kanayama A, Seth RB, Sun L, Ea CK, Hong M, Shaito A, Chiu YH, Deng L, Chen ZJ. TAB2 and TAB3 activate the NF-kappa B pathway through binding to polyubiquitin chains. Mol Cell 2004; 15: 535-48
81. Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell JD. NEMO is a sensor of Lys 63-linked polyubiquitination and functions in NF-kappa B activation. Nat Cell Biol 2006; 8: 398-406
82. Baker R, Ghosh S. Direct activation of protein kinases by ubiquitin. J Mol Cell Biol 2010; 2: 20-2
83. Zeng W, Sun L, Jiang X, Chen X, Hou F, Adhikari A, Xu M, Chen ZJ. Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell 2010; 141: 315-30
84. Pertel T, Hausmann S, Morger D, Zuger S, Guerra J, Lascano J, Reinhard C, Santoni FA, Uchil PD, Chatel L, Bisiaux A, Albert ML, Strambio-De-Castillia C, Mothes W, Pizzato M, Grutter MG, Luban J. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 2011; 472: 361-5
85. UniProt Consortium. Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res 2011; 39: D214-19
86. Timm T, Marx A, Panneerselvam S, Mandelkow E, Mandelkow EM. Structure and regulation of MARK, a kinase involved in abnormal phosphorylation of Tau protein. BMC Neurosci 2008; 9: S9
87. Götz J, Gladbach A, Pennanen L, van Eersel J, Schild A, David D, Ittner LM. Animal models reveal role for tau phosphorylation in human disease. Biochim Biophys Acta 2010; 1802: 860-71
88. Mi K, Johnson GV. The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2006; 3: 449-63
89. Chatterjee S, Sang TK, Lawless GM, Jackson GR. Dissociation of tau toxicity and phosphorylation: role of GSK-3 beta, MARK and Cdk5 in a Drosophila model. Hum Mol Genet 2009; 18: 164-77
90. Jaleel M, Villa F, Deak M, Toth R, Prescott AR, Van Aalten DM, Alessi DR. The ubiquitin-associated domain of AMPK-related kinases regulates conformation and LKB1-mediated phosphorylation and activation. Biochem J 2006; 394: 545-55
91. Marx A, Nugoor C, Muller J, Panneerselvam S, Timm T, Bilang M, Mylonas E, Svergun DI, Mandelkow EM, Mandelkow E. Structural variations in the catalytic and ubiquitin-associated domains of microtubule-associated protein/microtubule affinity regulating kinase (MARK) 1 and MARK2. J Biol Chem 2006; 281: 27586-99
92. Panneerselvam S, Marx A, Mandelkow EM, Mandelkow E. Structure of the catalytic and ubiquitin-associated domains of the protein kinase MARK/Par-1. Structure 2006; 14: 173-83
93. Marx A, Nugoor C, Panneerselvam S, Mandelkow E. Structure and function of polarity-inducing kinase family MARK/Par-1 within the branch of AMPK/Snf1-related kinases. FASEB J 2010; 24: 1637-48
94. Murphy JM, Korzhnev DM, Ceccarelli DF, Briant DJ, Zarrine-Afsar A, Sicheri F, Kay LE, Pawson T. Conformational instability of the MARK3 UBA domain compromises ubiquitin recognition and promotes interaction with the adjacent kinase domain. Proc Natl Acad Sci U S A 2007; 104: 14336-41
95. Raasi S, Orlov I, Fleming KG, Pickart CM. Binding of polyubiquitin chains to ubiquitin-associated (UBA) domains of HHR23A. J Mol Biol 2004; 341: 1367-79
96. Varadan R, Assfalg M, Raasi S, Pickart C, Fushman D. Structural determinants for selective recognition of a Lys48-linked polyubiquitin chain by a UBA domain. Mol Cell 2005; 18: 687-98
97. Al-Hakim AK, Zagorska A, Chapman L, Deak M, Peggie M, Alessi DR. Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-inked polyubiquitin chains. Biochem J 2008; 411: 249-60
98. Thomson DM, Hansen MD, Winder WW. Regulation of the AMPK-related protein kinases by ubiquitination. Biochem J 2008; 411: e9-10
99. Haglund K, Stenmark H. Working out coupled monoubiquitination. Nat Cell Biol 2006; 8: 1218-19
100. Bish RA, Fregoso OI, Piccini A, Myers MP. Conjugation of complex polyubiquitin chains to WRNIP1. J Proteome Res 2008; 7: 3481-9
101. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007; 184: 69-91
102. Ray B, Lahiri DK. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol 2009; 9: 434-44
103. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer's disease. Arch Pharm Res 2010; 33: 1539-56
104. Herrmann O, Baumann B, de Lorenzi R, Muhammad S, Zhang W, Kleesiek J, Malfertheiner M, Köhrmann M, Potrovita I, Maegele I, Beyer C, Burke JR, Hasan MT, Bujard H, Wirth T, Pasparakis M, Schwaninger M. IKK mediates ischemia-induced neuronal death. Nat Med 2005; 11: 1322-9
105. Sanchez-Ponce D, Tapia M, Muñoz A, Garrido JJ. New role of IKK alpha/beta phosphorylated I kappa B alpha in axon outgrowth and axon initial segment development. Mol Cell Neurosci 2008; 37: 832-44
106. Jadrich J, O'Connor MB, Coucouvanis E. Expression of TAK1, a mediator of TGF-beta and BMP signaling, during mouse embryonic development. Gene Expr Patterns 2003; 3: 131-4
107. Kim YS, Harry GJ, Kang HS, Goulding D, Wine RN, Kissling GE, Liao G, Jetten AM. Altered cerebellar development in nuclear receptor TAK1/TR4 null mice is associated with deficits in GLAST(+) glia, alterations in social behavior, motor learning, startle reactivity, and microglia. Cerebellum 2010; 9: 310-23
108. Neubert M, Ridder DA, Bargiotas P, Akira S, Schwaninger M. Acute inhibition of TAK1 protects against neuronal death in cerebral ischemia. Cell Death Differ 2011; 18: 1521-30
109. Zeng KW, Fu H, Liu GX, Wang XM. Icariin attenuates lipopolysaccharide-induced microglial activation and resultant death of neurons by inhibiting TAK1/IKK/NF-kappa B and JNK/p38 MAPK pathways. Int Immunopharmacol 2010; 10: 668-78
110. Buggia-Prevot V, Sevalle J, Rossner S, Checler F. NF kappa B-dependent control of BACE1 promoter transactivation by A beta 42. J Biol Chem 2008; 283: 10037-47
111. Guglielmotto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, Catalano MG, Smith MA, Perry G, Danni O, Boccuzzi G, Tabaton M. AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol Aging 2012; 33: 196.e13-27
112. Brownlees J, Irving NG, Brion JP, Gibb BJ, Wagner U, Woodgett J, Miller CC. Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3 beta transgenes. Neuroreport 1997; 8: 3251-5
113. Bian F, Nath R, Sobocinski G, Booher RN, Lipinski WJ, Callahan MJ, Pack A, Wang KK, Walker LC. Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. J Comp Neurol 2002; 446: 257-66
114. Nishimura I, Yang Y, Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 2004; 116: 671-82
115. Wang DL, Ling ZQ, Cao FY, Zhu LQ, Wang JZ. Melatonin attenuates isoproterenol-induced protein kinase A overactivation and tau hyperphosphorylation in rat brain. J Pineal Res 2004; 37: 11-16
116. Yamamoto H, Hiragami Y, Murayama M, Ishizuka K, Kawahara M, Takashima A. Phosphorylation of tau at serine 416 by Ca2+/calmodulin-dependent protein kinase II in neuronal soma in brain. J Neurochem 2005; 94: 1438-47
117. Kins S, Kurosinski P, Nitsch RM, Götz J. Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol 2003; 163: 833-43
118. Echeverria V, Ducatenzeiler A, Dowd E, Jänne J, Grant SM, Szyf M, Wandosell F, Avila J, Grimm H, Dunnett SB, Hartmann T, Alhonen L, Cuello AC. Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience 2004; 129: 583-92
119. Sato S, Xu J, Okuyama S, Martinez LB, Walsh SM, Jacobsen MT, Swan RJ, Schlautman JD, Ciborowski P, Ikezu T. Spatial Learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1. J Neurosci 2008; 28: 14511-21